🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 11 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 28/07/2006 | 33,41 | 34,33 | 32,95 | 34,25 | +2,64% | 4,13% | 983.400 |
| 27/07/2006 | 35,07 | 35,10 | 32,60 | 33,37 | -6,13% | 7,13% | 1.958.300 |
| 26/07/2006 | 35,32 | 35,94 | 34,76 | 35,55 | -0,14% | 3,34% | 544.300 |
| 25/07/2006 | 34,95 | 35,77 | 34,62 | 35,60 | +1,57% | 3,29% | 776.100 |
| 24/07/2006 | 34,37 | 35,38 | 34,25 | 35,05 | +2,01% | 3,29% | 713.700 |
| 21/07/2006 | 35,13 | 35,13 | 33,69 | 34,36 | -1,80% | 4,10% | 824.200 |
| 20/07/2006 | 35,37 | 35,87 | 34,84 | 34,99 | -0,71% | 2,91% | 1.086.500 |
| 19/07/2006 | 33,04 | 35,35 | 32,78 | 35,24 | +6,98% | 7,78% | 1.314.000 |
| 18/07/2006 | 33,58 | 33,96 | 32,26 | 32,94 | -1,70% | 5,06% | 995.400 |
| 17/07/2006 | 34,24 | 34,70 | 33,32 | 33,51 | -2,27% | 4,03% | 861.200 |
| 14/07/2006 | 35,30 | 35,38 | 33,66 | 34,29 | -0,92% | 4,87% | 1.296.500 |
| 13/07/2006 | 36,00 | 36,12 | 34,26 | 34,61 | -4,23% | 5,17% | 1.076.500 |
| 12/07/2006 | 35,70 | 37,10 | 35,60 | 36,14 | +0,84% | 4,20% | 1.251.000 |
| 11/07/2006 | 35,14 | 35,91 | 34,82 | 35,84 | +1,76% | 3,10% | 782.800 |
| 10/07/2006 | 36,00 | 36,70 | 34,90 | 35,22 | -1,92% | 5,00% | 684.700 |
| 07/07/2006 | 36,20 | 36,38 | 35,40 | 35,91 | -1,32% | 2,71% | 1.154.000 |
| 06/07/2006 | 35,60 | 36,86 | 35,30 | 36,39 | +2,33% | 4,38% | 988.300 |
| 05/07/2006 | 36,25 | 36,25 | 35,25 | 35,56 | -2,76% | 2,76% | 1.625.500 |
| 03/07/2006 | 36,45 | 36,83 | 35,52 | 36,57 | -0,38% | 3,59% | 1.151.600 |
| 30/06/2006 | 36,01 | 36,75 | 34,13 | 36,71 | +14,61% | 7,28% | 14.515.300 |
| 29/06/2006 | 30,12 | 32,03 | 29,69 | 32,03 | +8,14% | 7,77% | 1.639.800 |
| 28/06/2006 | 30,39 | 30,64 | 29,18 | 29,62 | -1,99% | 4,80% | 1.399.100 |
| 27/06/2006 | 32,03 | 32,19 | 29,94 | 30,22 | -6,00% | 7,02% | 1.070.800 |
| 26/06/2006 | 31,85 | 32,53 | 31,65 | 32,15 | +1,55% | 2,76% | 815.100 |
| 23/06/2006 | 30,81 | 31,95 | 30,14 | 31,66 | +2,16% | 5,87% | 754.400 |
| 22/06/2006 | 32,58 | 32,76 | 30,82 | 30,99 | -5,14% | 5,95% | 1.512.800 |
| 21/06/2006 | 31,15 | 32,97 | 30,56 | 32,67 | +4,78% | 7,74% | 1.203.300 |
| 20/06/2006 | 31,14 | 31,65 | 30,73 | 31,18 | +0,39% | 2,95% | 952.600 |
| 19/06/2006 | 32,97 | 32,98 | 30,79 | 31,06 | -6,05% | 6,64% | 1.451.900 |
| 16/06/2006 | 33,00 | 33,27 | 32,28 | 33,06 | +0,24% | 3,00% | 2.751.800 |